Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients.

导出 OA

翻译打印收藏纠错

第一作者： Elena,Atanasova

第一单位： Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.

作者： Elena,Atanasova ^[1] ; Dragana,Milosevic ^[2] ; Svetlana,Bornschlegl ^[1] ; Karen P,Krucker ^[3] ; Eapen K,Jacob ^[4] ; Eva M,Carmona Porquera ^[5] ; Dagny K,Anderson ^[5] ; Ashley M,Egan ^[5] ; Andrew H,Limper ^[5] ; Allan B,Dietz ^[6]

作者单位： Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA. ^[1] Department of Laboratory Medicine and Pathology, Divisions of Clinical Biochemistry and Immunology, Mayo Clinic College of Medicine, Rochester, MN, USA. ^[2] Divisions of Transfusion Medicine and Experimental Pathology, Immune Progenitor and Cell Therapeutics (IMPACT) Lab, Mayo Clinic College of Medicine, Rochester, MN, USA. ^[3] Division of Transfusion Medicine, Mayo Clinic, Rochester, MN, USA. ^[4] Thoracic Diseases Research Unit, Division of Pulmonary Critical Care and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. ^[5] Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA. Dietz.allan@mayo.edu. ^[6] Divisions of Transfusion Medicine and Experimental Pathology, Immune Progenitor and Cell Therapeutics (IMPACT) Lab, Mayo Clinic College of Medicine, Rochester, MN, USA. Dietz.allan@mayo.edu. ^[7]

关键词 Idiopathic pulmonary fibrosis Immunology Mesenchymal stem cells Therapy

主题词动物(Animals);人类(Humans);特发性肺纤维化(Idiopathic Pulmonary Fibrosis);肺(Lung);间质干细胞(Mesenchymal Stem Cells);骨生成(Osteogenesis)

DOI 10.1186/s13287-021-02692-0

PMID 35101101

发布时间 2023-11-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交